Previous 10 | Next 10 |
Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...
The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Kymera Therapeutics' ( NASDAQ: KYMR ) KT-333 to treat Cutaneous T-cell Lymphoma (CTCL). CTCL is rare form of cancer which begins in a type of white blood cells called T cells (T lymphoc...
WATERTOWN, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the U.S. Food and Drug Administra...
WATERTOWN, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, announced that Nello Mainolfi, PhD, Co-Founder, Preside...
Kymera Therapeutics ( NASDAQ: KYMR ) signed an agreement with certain existing and new investors to raise gross proceeds of ~$150M. The company will sell ~2.77M common shares at $26 apiece and pre-funded warrants to buy up to 3M shares at $25.9999 per pre-funded w...
WATERTOWN, Mass., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, has entered into a securities purchase agreement with c...
Jefferies has initiated Kymera Therapeutics ( NASDAQ: KYMR ) as a buy citing the company's platform and targeted protein degredation molecules in the development of treatments for oncology and autoimmune conditions. The firm has a $40 price target (~18% upside based on Fri...
Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience WINSTON-SALEM, N....
Kymera Therapeutics press release ( NASDAQ: KYMR ): Q2 GAAP EPS of -$0.78 misses by $0.08 . Revenue of $11.51M (-37.9% Y/Y) misses by $3.46M . “Kymera has made strong progress, dosing patients in our three first-in-class clinical programs and advancing o...
Initiated dosing in patient cohort (Part C) of IRAK4 degrader KT-474 Phase 1 trial, on track for data by year end Phase 1 patient studies initiated for STAT3 (KT-333) and IRAKIMiD (KT-413) oncology programs, initial data to be shared by year end June 30, 2022 cash ...
News, Short Squeeze, Breakout and More Instantly...
Kymera Therapeutics Inc. Company Name:
KYMR Stock Symbol:
NASDAQ Market:
Kymera Therapeutics Inc. Website:
2024-07-12 19:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 13:30:00 ET Shares of Kymera Therapeutics (NASDAQ: KYMR) were soaring 18.4% higher as of 11:28 a.m. ET on Tuesday. The big jump came after the clinical-stage biopharmaceutical company announced on Monday that its partner, Sanofi , plans to expand the ongoing phase 2 s...
WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside ...